Reviewing China Biologic Products (CBPO) and Ra Pharmctl (RARX)

China Biologic Products (NASDAQ: CBPO) and Ra Pharmctl (NASDAQ:RARX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership.


This table compares China Biologic Products and Ra Pharmctl’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
China Biologic Products 31.55% 21.86% 18.83%
Ra Pharmctl N/A -64.75% -44.33%

Institutional and Insider Ownership

72.8% of China Biologic Products shares are owned by institutional investors. Comparatively, 66.3% of Ra Pharmctl shares are owned by institutional investors. 2.7% of China Biologic Products shares are owned by company insiders. Comparatively, 14.5% of Ra Pharmctl shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares China Biologic Products and Ra Pharmctl’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
China Biologic Products $344.89 million 7.17 $155.64 million $3.87 23.47
Ra Pharmctl N/A N/A -$42.07 million ($16.01) -0.94

China Biologic Products has higher revenue and earnings than Ra Pharmctl. Ra Pharmctl is trading at a lower price-to-earnings ratio than China Biologic Products, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for China Biologic Products and Ra Pharmctl, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
China Biologic Products 0 1 2 0 2.67
Ra Pharmctl 0 0 5 0 3.00

China Biologic Products presently has a consensus price target of $137.50, indicating a potential upside of 51.42%. Ra Pharmctl has a consensus price target of $25.60, indicating a potential upside of 69.65%. Given Ra Pharmctl’s stronger consensus rating and higher probable upside, analysts plainly believe Ra Pharmctl is more favorable than China Biologic Products.


China Biologic Products beats Ra Pharmctl on 7 of the 11 factors compared between the two stocks.

China Biologic Products Company Profile

China Biologic Products Holdings, Inc. is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company’s products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).

Ra Pharmctl Company Profile

Ra Pharmaceuticals, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade. It has leveraged the Extreme Diversity peptide chemistry platform to develop a portfolio of products that selectively inhibit the complement system and other immune targets. Its main program, RA101495, is a macrocyclic peptide inhibitor of complement component 5 (C5), which is in Phase I stage of development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). RA101495 binds a site on the C5 protein to inhibit cleavage into C5a and C5b, thereby preventing red blood cell lysis by inhibiting the production and assembly of the membrane attack complex (MAC). RA101495 is being developed as an alternative to eculizumab therapy for patients with PNH.

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with's FREE daily email newsletter.

Leave a Reply